Amgen
Large-cap biotechnology company pairing its human-genetics datasets with generative-AI protein design through its Generate Biomedicines collaboration.
- Company type
- Large biotechnology company
- Headquarters
- Thousand Oaks, United States
- Website
- https://www.amgen.com
- Profile last verified
- 2026-07-29
AI Partnerships & Deployments
- 2024-05-20 — Enterprise rollout of Microsoft 365 Copilot (Microsoft (Microsoft 365 Copilot)). Amgen deployed Microsoft 365 Copilot across its global workforce to boost employee productivity, describing it as part of a broader AI and advanced-analytics strategy. Microsoft's customer story reports the rollout reaching tens of thousands of employees; no financial terms were disclosed. Source: Microsoft customer story (accessed 2026-07-29)
- 2024-01-04 — Expansion of the Generate Biomedicines collaboration (Generate Biomedicines). Generate:Biomedicines announced an expansion of its collaboration agreement with Amgen, disclosed alongside clinical-pipeline updates ahead of the 42nd J.P. Morgan Healthcare Conference. Expansion terms were not disclosed. Source: Business Wire (Generate:Biomedicines release) (accessed 2026-07-29)
- 2022-01-06 — Multi-target, multi-modality research collaboration with Generate Biomedicines (Generate Biomedicines). Research collaboration to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities using Generate's machine-learning platform. Amgen paid $50 million upfront for the initial five programs, with a potential transaction value of $1.9 billion plus royalties and an option to nominate up to five additional programs. Disclosed: $50M upfront; potential value $1.9B plus royalties. Source: Amgen press release (accessed 2026-07-29)